348 related articles for article (PubMed ID: 16198659)
1. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
Granfors MT; Backman JT; Laitila J; Neuvonen PJ
Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
[TBL] [Abstract][Full Text] [Related]
2. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
[TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
[TBL] [Abstract][Full Text] [Related]
4. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
Backman JT; Karjalainen MJ; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Sep; 62(3):345-57. PubMed ID: 16934051
[TBL] [Abstract][Full Text] [Related]
5. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
Backman JT; Granfors MT; Neuvonen PJ
Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
7. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects.
Henney HR; Fitzpatrick A; Stewart J; Runyan JD
Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586
[TBL] [Abstract][Full Text] [Related]
8. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
Ferreira AC; Montes MB; Franceschini SA; Toloi MR
Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
[TBL] [Abstract][Full Text] [Related]
9. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Griffith SG; Dai Y
Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
[TBL] [Abstract][Full Text] [Related]
10. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
11. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.
Momo K; Homma M; Osaka Y; Inomata S; Tanaka M; Kohda Y
J Clin Pharmacol; 2010 Mar; 50(3):331-7. PubMed ID: 19789372
[TBL] [Abstract][Full Text] [Related]
12. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
Backman JT; Schröder MT; Neuvonen PJ
Eur J Clin Pharmacol; 2008 Jan; 64(1):17-24. PubMed ID: 17955229
[TBL] [Abstract][Full Text] [Related]
13. The effect of oral contraceptives on protein metabolism.
Amatayakul K; Laokuldilok T; Koottathep S; Dejsarai W; Prapamontol T; Srirak N; Tansuhaj A; Uttaravichai C
J Med Assoc Thai; 1994 Oct; 77(10):509-16. PubMed ID: 7745371
[TBL] [Abstract][Full Text] [Related]
14. The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism.
Hilli J; Korhonen T; Turpeinen M; Hokkanen J; Mattila S; Laine K
J Clin Pharmacol; 2008 Aug; 48(8):986-94. PubMed ID: 18490497
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.
Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR
Clin Pharmacol Ther; 1998 Dec; 64(6):597-602. PubMed ID: 9871424
[TBL] [Abstract][Full Text] [Related]
16. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein alterations from a triphasic oral contraceptive containing ethinyl estradiol and gestodene. A 12-month trial.
Moutos DM; Zacur HA; Bachorik PS; Wallach EE
J Reprod Med; 1994 Sep; 39(9):720-4. PubMed ID: 7807486
[TBL] [Abstract][Full Text] [Related]
18. Plasma rifampicin levels during oral contraception.
Gupta KC; Joshi JV; Anklesaria PS; Shah RS; Satoskar RS
J Assoc Physicians India; 1988 Jun; 36(6):365-6. PubMed ID: 3182712
[TBL] [Abstract][Full Text] [Related]
19. A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state.
Shellenberger MK; Groves L; Shah J; Novack GD
Drug Metab Dispos; 1999 Feb; 27(2):201-4. PubMed ID: 9929503
[TBL] [Abstract][Full Text] [Related]
20. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]